ABT

Abbott Laboratories 2003 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2003. Abbott Laboratories is a diversified healthcare company operating through five reportable segments: Pharmaceutical Products, Diagnostic Products, Hospital Products, Ross Products, and International. The company also holds a 50% interest in TAP Pharmaceutical Products Inc. A significant strategic development in 2003 was the announcement of a plan to spin off its core hospital products business into a separate publicly traded company, Hospira, Inc., expected to occur in the first half of 2004.

Key Financial Metrics

Dividends: Quarterly dividends declared were $0.245 per share in 2003 ($0.98 annualized) compared to $0.235 per share in 2002.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 11.3% year-over-year, driven by a 1.0% price increase, 6.8% volume growth, and a 3.5% favorable foreign exchange impact.
• Profitability: Net earnings decreased slightly by 1.4% to $2.75 billion. This decline was primarily due to a $614 million pre-tax charge related to the settlement of an industry-wide investigation into the enteral nutritional business (Ross Products) and a $88 million impairment charge for Abbokinase assets.
• Segment Performance: Pharmaceutical Products sales grew 22.3%, led by the launch of Humira ($246 million in U.S. sales). Diagnostic Products sales grew 5.0%, aided by a weaker U.S. dollar. Hospital Products sales grew 3.3%.
• Debt Reduction: Long-term debt decreased by approximately $822 million as the company utilized operating cash flows to pay down commercial paper borrowings.

Guidance, Outlook, and Risks

• Hospira Spin-off: Abbott expects to distribute Hospira shares to shareholders in H1 2004. Hospira will assume approximately $750 million of debt. Post-spin-off, Hospira results will be reported as discontinued operations.
• Product Outlook: Abbott forecasts worldwide sales of Humira to exceed $700 million in 2004. The company is focusing on the global launch of Humira and the integration of recent acquisitions (ZonePerfect, Integrated Vascular Systems, Spinal Concepts).
• Acquisitions: In January 2004, Abbott announced agreements to acquire TheraSense Inc. ($1.2 billion) and i-STAT Corporation ($392 million). These are expected to close in Q2 2004, with anticipated charges of $171 million for in-process R&D and $115 million for restructuring.
• Patent Expirations: Key patent expirations include clarithromycin (Biaxin) in 2005, divalproex sodium (Depakote) in 2008, and lansoprazole (Prevacid) in 2009. Abbott is defending patents for TriCor against competitors.
• Legal and Regulatory: The company faces ongoing litigation regarding pricing practices (antitrust suits), product liability (Meridia, OxyContin), and patent infringement. Abbott settled the enteral nutritional investigation for $614 million in 2003. The FDA has cleared Abbott's Lake County diagnostic facility, allowing the reintroduction of previously restricted products.

Investor Verification Checklist

• Settlement Impact: Verify the full financial impact of the $614 million Ross enteral nutritional settlement and the $88 million Abbokinase impairment on 2003 earnings.
• Hospira Spin-off Timing: Confirm the final approval and execution date of the Hospira spin-off to understand the composition of future "continuing operations."
• Patent Litigation: Monitor the status of patent challenges for TriCor and the expiration timeline for Biaxin (2005) and Depakote (2008).
• Acquisition Integration: Assess the integration progress and financial performance of the TheraSense and i-STAT acquisitions post-closing in 2004.
• Rebate Reserves: Review the adequacy of sales rebate reserves, which totaled approximately $2.6 billion in 2003, given the sensitivity of net sales to rebate rates.